Loading cancer entity…
Loading cancer entity…
Clinical trials
41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06033092 | Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion(TOLERANT) | completed | Phase 2 | 110 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease(TBCRC042) | completed | Phase 2 | 84 | Julie NangiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02314156 | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | completed | Phase 2 | 67 | Northwestern UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT01849250 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2021 | clinicaltrials |
| NCT01869764 | Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer | completed | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Oct 30, 2019 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials